Biomark Diagnostics, Inc. · CSE:BUX
Biomark Diagnostics — Investor Presentation (September 2025)
23 slides from Biomark Diagnostics's investor presentation, September 2025
Slide 1: Investor Presentation Sept 2025
REDEFINING EARLY-STAGE CANCER DETECTION THROUGH LIQUID BIOPSY, METABOLOMICS, MACHINE LEARNING, AND ARTIFICIAL INTELLIGENCE INVESTOR PRESENTATION SEPT 2025 CSE: BUX / OTCQB: BMKDF
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation and the accompanying oral presentation have been prepared by BioMark Diagnostics, Inc. ("BioMark", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as,
Slide 3: Who We Are
WHO WE ARE • Founded in 2014 BioMark Diagnostics • Developer of a liquid biopsy-based platform using (CSE: BUX / OTC: BMKDF) metabolomics while leveraging machine learning and AI (Note: All $ = CDN) to develop robust panel of biomarkers Stock Price (as of 9/11/25) $0.36 • Over 25 patents across 9 di
Slide 4: BioMark Leadership
BIOMARK LEADERSHIP Rashid A. Bux | Founder & CEO • Co-founder and COO of Optima Health and KKT Spinecentres • Founder and President of Homeworks • MBA from University of Western Ontario • B.S. in Business Administration from Miami University, OH Guoyu (Gina) Huang | CFO Dr. Jean-Francois Haince | CS
Slide 5: Strategic and Scientific Advisors
STRATEGIC AND SCIENTIFIC ADVISORS Strategic Mr. Alfred R. Berkeley Vice Admiral Kevin Cosgriff Strategic and Financial Advisor Innovation and Investment Strategy Dr. Randolph Ford Theresa Peterson AI and ML Strategic Advisor Government Liaison and Community Engagement Scientific Dr. David Wishart Dr
Slide 6: You May Not Have Heard of Us… But Many Others Have
YOU MAY NOT HAVE HEARD OF US… BUT MANY OTHERS HAVE Disclosed Pharma & Equipment Collaborators Disclosed Hospital Collaborators Canadian Collaborators Disclosed Academic Collaborators (Healthcare & Government Agencies) CSE: BUX / OTCQB: BMKDF 6
Slide 7: Lung Cancer Overview
LUNG CANCER OVERVIEW -* NN.
Slide 8: Lung Cancer – The Big Picture
LUNG CANCER – THE BIG PICTURE Most common • Lung cancer is the most common cancer in the world and accounts for 1 in 5 of all cancer deaths • In U.S., 240,000 new cases/yr with 134,000 deaths Deadly • 5-year survival rate of 19% is lower than many other leading cancers that also have official recomm
Slide 9: To Make an Impact, We Must Stage-Shift Lung Cancer Detection
TO MAKE AN IMPACT, WE MUST STAGE-SHIFT LUNG CANCER DETECTION 5-Year Relative Survival for Common Cancers by Cost of Cancer Management by Stage at Stage at Diagnosis* Diagnosis among Medicare Patients** Based on cancers diagnosed during 2011 to 2017 and follow-up of patients Based on ~500,000 Medicar
Slide 10: Limitations of LDCT for Lung Cancer Screening
LIMITATIONS OF LDCT FOR LUNG CANCER SCREENING • LDCT requires expensive scanning instruments more commonly found in urban medical/academic centers and clinics and not typically found in rural and/or underprivileged settings, where incident of smoking is higher, so accessibility is a limitation for s
Slide 11: Metabolomics and Our Diagnostic Platform
METABOLOMICS AND OUR DIAGNOSTIC PLATFORM
Slide 12: Lung Cancer Is a Metabolic Disease, So We Use Metabolomics
LUNG CANCER, LIKE …WHICH IS WHY WE ALL CANCER, IS A USE METABOLOMICS METABOLIC DISEASE… AS OUR FOUNDATION me·tab·o·lo·mics | \ mə-ˈta-bə-ˌlō-miks a form of clinical chemistry that uses advanced analytical techniques to measure the complete collection of “small molecules” found in a given biologi
Slide 13: Metabolomics Is the New Kid on the Block
METABOLOMICS IS THE “NEW KID ON THE BLOCK” • There are differences in the genomes of cancer cells and tissues in different cancer patients • This heterogeneity of cancer cells impacts the accuracy and applicability of many diagnostic markers for genes and proteins • The many genomic-based approaches
Slide 14: Some Life Sciences Leaders Are Already Looking Beyond NGS
SOME LIFE SCIENCES LEADERS ARE ALREADY LOOKING BEYOND NGS “ The last 20 years were dominated by genomics because the technology was there, and that's a good thing, and genomics, of course, is very important in an overall multiomics and systems biology approach. But proteomics and related fields - gl
Slide 15: Comparison of Liquid Biopsy Analytes for Early Detection of Lung Cancer
COMPARISON OF LIQUID BIOPSY ANALYTES FOR EARLY DETECTION OF LUNG CANCER Analyte Advantages Challenges References ctDNA has low concentration compared ctDNA, cfDNA mutation analysis Elevated in cancer patients; genetic to germline cfDNA; low minor allele Bettegowda et al25, Duffy117 alterations repre
Slide 16: Lung Cancer Screening Competitors
LUNG CANCER SCREENING COMPETITORS Competitor Offering Trials/Focus Mkt Cap & Capital Raise Initiated 15,000 patient prospective CASCADE-LUNG screening trial Blood-based lung cancer screening test in May 2022. using “fragmentomics” (DNA fragment Private company – founded in 2019 DELFI patterns, or ce
Slide 17: Clinical Studies and Validation Projects in Progress
CLINICAL STUDIES AND VALIDATION PROJECTS IN PROGRESS Early Lung Cancer KOL in Canada, the US and Europe • Completed >800 in an independent retrospective sample study following a 260-sample trial at IUCP Quebec. Expanded the sample size to include more subtypes, other lung diseases, and different can
Slide 18: Our Platform Pipeline
OUR PLATFORM PIPELINE Our metabolomics-based platform isn’t just for lung cancer detection • We have expanded it to include other hard-to-detect and treat cancers like breast cancer, head and neck, and glioblastoma • Presented strong early-stage data on breast cancer data and sub-types at recent ann
Slide 19: Milestone Overview
MILESTONE OVERVIEW Seminal data Strong data (i.e. Expand lab capacity and First commercial expected by early sensitivity >90%) in throughput. Lab will be CLIA revenue from early 2025 from the lung Stage 1 and 2 patients and ISO certified before detection lung cancer cancer detection and could be piv
Slide 20: Early Lung Cancer Metabolic Assay
EARLY LUNG CANCER METABOLIC ASSAY DESIGNED FOR EASY DEPLOYMENT • Use quantitative mass spectrometry (MS) methods with standard instruments common in diagnostic clinical laboratories across Canada and USA • Lung cancer metabolites are easily measured: ~300 µL of plasma required • Time to perform the
Slide 21: Workflow
Workflow CSE: BUX / OTCQB: BMKDF 21
Slide 22: Important Milestones and Catalysts next 6-12 months
Important Milestones and Catalysts next 6-12 months Commercialization • Lab certification and accreditations – Underway, starting with ISO 15189 and followed by CLIA CAP in early 2026 • Expand lab capacity and automation • Data readout on the large multimodal lung cancer trials • Launch of lung canc
Slide 23: Contact Details
REDEFINING EARLY-STAGE Contact Details CANCER DETECTION THROUGH Rashid Bux LIQUID BIOPSY, METABOLOMICS, Founder and CEO MACHINE LEARNING, AND rahmed@biomarkdiagnostics.com ARTIFICIAL INTELLIGENCE Mobile: 604.836.6950 www.biomarkdiagnostics.com CSE: BUX / OTCQB: BMKDF
BioMark Diagnostics — Investor Presentation (September 2025) on 6ix